CIITA Antibody - BSA Free

The transactivator CIITA regulates basal and interferon-induced expression of Major Histocompatibility Complex class II genes. CIITA restores expression of all MHC class II gene expression in mutant cells and corrects regulatory defects of MHC class II genes. Antibodies to this transactivator are useful in the study of diseases of pathological MHC class II expression. Antigen can be obtained from Raji cell lysates. Typically levels of CIITA expression are too low to detect endogenous levels of protein expression. Transiently transfected cells are usually employed to study this transcription factor.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 2 applications: ICC/IF, IF/IHC.

Showing Publications 1 - 2 of 2.

Publications using NBP2-59072	Applications	Species
Jeong H, Lee H, Kim H et al. Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non-small-cell lung carcinoma iScience 2022-11-01 [PMID: 36339256] (ICC/IF, Human)	ICC/IF	Human
Xue Y, Tang D, Li SJ et al. Link between CIITA rs3087456 polymorphism and the risk of laryngeal squamous cell carcinoma in a Chinese population Pathol. Res. Pract. 2019-12-18 [PMID: 31870593] (IF/IHC, Human)	IF/IHC	Human

Array NBP2-59072

• CIITA Antibodies
• CIITA Lysate
• CIITA Proteins